Related Experiment Video
Updated: Jul 5, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Lymphocyte subsets in renal transplant recipients with de novo genitourinary malignancies
Guillaume Guichard1, Jean Michel Rebibou, Didier Ducloux
1Department of Urology and Renal Transplantation, University Hospital, Besançon, France.
Introduction:
The incidence of genitourinary tumors (GUT) in renal transplant recipients (RTR) is higher than in the general population. We previously reported that CD4 lymphocytopenia is associated with a high incidence of skin cancer in RTR. Here, we investigate whether persistent CD4 T cell lymphopenia is associated with GUT occurrence.
Patients And Methods:
A total of 433 patients were included in this study. All patients underwent annually systematic lymphocyte subset (CD3, CD4, CD8, CD19) determination by flow cytometry.
Results And Conclusion:
During the follow-up period, 13 patients developed GUT: 6 patients a prostate adenocarcinoma (incidence 0.06%/year) and 7 patients a renal cell carcinoma (incidence 0.07%/year). The patients with GUT were older than those without. Both groups did not differ in posttransplant duration, dialysis mode and duration, induction regimen, or acute rejection history. No persistent CD4 lymphopenia was observed in the patients with GUT. Although CD4 T cell lymphopenia is associated with skin cancer in long-term RTR, it did not appear to be a risk factor for GUT. This suggests that other factors encountered in the setting of kidney transplantation (e.g., immunosuppressive drugs, end-stage renal failure, etc.) favor the development of GUT in RTR.
More Related Videos
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Cell-mediated Immune Responses
